Quantcast
 
Read Larry Connors' blogShort Term Trading Strategies


IMUC

ImmunoCellular reports promising data from Phase I brain cancer trial - 10/29 - 05:05 AM ET

IMUC: Presents Positive Data from Phase I Trial of ICT-107 in Brain Cancer - 10/27 - 10:06 AM ET

ImmunoCellular Therapeutics Presents Data from Phase I Trial of ICT-107 Demonstrating Significant Increase in Tumor-Free Progression in Patients with Brain Cancer - 10/27 - 08:00 AM ET

ImmunoCellular Therapeutics to Present Today Data From Phase I Clinical Trial of ICT-107 at Annual Meeting of Congress of Neurological Surgeons - 10/26 - 08:00 AM ET

ImmunoCellular Therapeutics Files Patent Application Seeking IP Protetion - 10/22 - 11:55 PM ET

ImmunoCellular Therapeutics Engages Dr. Peter Brooks of the Maine Medical Center to Explore Cancer Stem Cell Targets - 10/22 - 08:32 AM ET

ImmunoCellular Therapeutics Applies for Key Patent Relating to Novel Antigen Targets for Its Monoclonal Antibody Product Candidate - 10/19 - 08:00 AM ET

ImmunoCellular Therapeutics Releases Results of Its Pilot Study of ICT-109 - 10/06 - 11:13 PM ET

ImmunoCellular Therapeutics' Antibody Shows Promise in Detecting Pancreatic and Lung Cancer in Serum Test - 09/30 - 08:00 AM ET

ImmunoCellular Therapeutics Announces Successful Humanization of Two Antibody Candidates - 09/23 - 08:00 AM ET

ImmunoCellular Therapeutics' Immunology Platform Featured in Report on the Future of Cancer Research - 09/17 - 08:45 AM ET

IMUC signs research and license option agreement with Roche - 09/10 - 06:07 PM ET

IMUC: Research and License Agreement w/Roche re ICT-69 Antibody - 09/09 - 09:41 AM ET

ImmunoCellular Therapeutics Enters into Research and License Option Agreement with Roche Group - 09/09 - 09:00 AM ET

ImmunoCellular Therapeutics To Present at Rodman and Renshaw's 11th Annual Healthcare Conference on Friday, September 11th - 09/03 - 08:00 AM ET

Equedia: ImmunoCellular Therapeutics, Ltd. Trading Informaton on Equedia - 08/18 - 12:23 PM ET

ImmunoCellular Therapeutics to Present at Southern California Investor Conference - 08/18 - 07:53 AM ET

ImmunoCellular Therapeutics Selects Torrey Pines Institute for Molecular Studies - 07/20 - 11:46 PM ET

IMUC retains services of Torrey Pines Institute to evaluate new drug candidate - 07/15 - 01:13 PM ET

ImmunoCellular Therapeutics Retains Services of Torrey Pines Institute for Molecular Studies and Renowned Immunologist to Evaluate Lead Product Candidate - 07/14 - 08:00 AM ET

Page 1 of 2     1  2      Previous  |  Next

<< Back to Stock Index

 

Most Popular News
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.